Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

EHR Alerts to Improve GLP-1 Medication and Continuous Glucose Monitor Prescribing in Primary Care

19. november 2026 oppdatert av: Montefiore Medical Center

Evaluation of Quality Improvement Initiative to Improve GLP-1 and CGM Prescription Rates

This randomized quality improvement study will evaluate whether pop-up alerts in the electronic health record (EHR) increase prescribing of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications and continuous glucose monitors (CGMs) for eligible patients with diabetes. The study will be conducted at nine Montefiore Medical Group primary care sites. Primary care providers will be randomly assigned to either receive the alerts or not receive them. The alerts will remind providers that a patient is eligible for a GLP-1 RA, a CGM, or both, and will help them choose the option covered by the patient's insurance. Providers in both groups will use their own clinical judgment in deciding whether to prescribe. The study will use information already recorded in patients' medical records.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

Primary care providers (physicians, physician assistants and nurse practitioners) are randomized 1:1, stratified by site type (teaching vs. non-teaching), prior GLP-1 RA prescribing, and eligible-patient volume. Approximately 121 providers will be randomized. The patients they see who meet eligibility criteria during the study period are the enrolled participants and are reflected in the enrollment count. Residents and their patients are excluded. For providers in the intervention arm, the alert is an Our Practice Advisory (OPA) in Epic that fires during qualifying in-person or telehealth primary care visits. Patients eligible for both a GLP-1 RA and a CGM trigger a single combined alert; patients eligible for only one trigger only that portion of the alert. Intervention-arm providers also receive education on using the alert. Outcomes are analyzed at the patient level using only each patient's first qualifying visit. The analysis uses mixed-effects logistic regression with a random effect for provider.

Note: The Albert Einstein College of Medicine Institutional Review Board (IRB) determined this quality improvement project does not meet the definition of human subjects research. An IRB determination letter is on file with this registration.

Studietype

Intervensjonell

Registrering (Antatt)

2989

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • New York
      • The Bronx, New York, Forente stater, 10467
        • Rekruttering
        • Montefiore Medical Center
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 85 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Meet Klompas definition of diabetes
  • Has at least one primary care visit, in-person or telehealth, during the study period
  • Is covered by Medicare or Medicaid

Additional inclusion criteria for the GLP-1 portion of the OPA alert:

  • GLP-1 component: HbA1c ≥ 9 on most recent lab test in the past 12 months and a BMI ≥ 25) OR BMI ≥ 30, and no GLP-1 prescription in the past 12 months

Additional inclusion criteria for the CGM portion of the OPA alert:

  • CGM component: Insulin prescription in the past 12 months and no CGM prescription in the past 12 months

Exclusion Criteria:

  • Patients seen by residents during their first visit

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Helsetjenesteforskning
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Our Practice Advisory (OPA) Alert

Education will be provided on the use of the alerts to PCPs in the intervention group. Providers will continue using clinical judgment for the appropriateness of the GLP-1 medication or CGM device for their patients.

Electronic Health Record (EHR) Our Practice Advisory, a pop-up electronic notification for clinical staff available at the time of a clinical encounter in the electronic medical record, recommending the insurance-preferred GLP-1 and/or a CGM, plus education for providers on using the alerts

Ingen inngripen: Usual Care (UC)

Providers continue usual care, with no alert. Providers will use clinical judgment for the appropriateness of the GLP-1 medication or CGM device for their patients.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Percentage of Eligible Patients Newly Prescribed an Insurance-preferred GLP-1 medication
Tidsramme: At the first qualifying primary care visit during the study period, up to 3 months

The percentage of patients meeting the GLP-1 RA alert eligibility criteria who are newly prescribed a GLP-1 RA covered by their insurance, as documented in the electronic health record. GLP-1 RAs not covered by the patient's insurance are not counted. Each patient's first qualifying visit during the study period is analyzed.

At the first qualifying primary care visit during the study period, up to 3 months
Percentage of Eligible Patients Newly Prescribed a CGM
Tidsramme: At the first qualifying primary care visit during the study period, up to 3 months

The percentage of patients meeting the CGM alert eligibility criteria who are newly prescribed a continuous glucose monitor (CGM), as documented in the electronic health record. Each patient's first qualifying visit during the study period is analyzed.

At the first qualifying primary care visit during the study period, up to 3 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Provider Response to the OPA alert
Tidsramme: Throughout the study period, up to 3 months

For the OPA arm only, providers interaction with the OPA alert will be evaluated based on the percentage of time the OPA alert fired and was either: ignored, declined, and approved. The unit of analysis are patients. Each nominal categorical variable will be summarized.

Throughout the study period, up to 3 months
Reasons for Declining the OPA alert
Tidsramme: Throughout the study period, up to 3 months

Among alert firings declined by providers in the OPA Alert arm, the percentage for each decline reason selected in the electronic health record will be summarized. The reasons are: Defer to Next Visit; Patient Declines; Chart Review Only; Does Not Meet Criteria; Financial Limitations; Treatment Ineffective; Patient Can't Tolerate. The unit of analysis are patients.

Throughout the study period, up to 3 months
Percentage of Eligible Patients Newly Prescribed an Insurance-preferred GLP-1 medication by Patient Characteristics
Tidsramme: Throughout the study period, up to 3 months

Primary outcome evaluated by patient Body Mass Index (BMI) category, HbA1c category, Insulin status, Age group, Sex, and Race/Ethnicity. The unit of analysis are patients.

Throughout the study period, up to 3 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Hovedetterforsker: Shivani Agarwal, MD, MPH, Montefiore Medical Center

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

28. oktober 2026

Primær fullføring (Antatt)

1. mars 2027

Studiet fullført (Antatt)

1. mars 2027

Datoer for studieregistrering

Først innsendt

5. november 2026

Først innsendt som oppfylte QC-kriteriene

17. november 2026

Først lagt ut (Faktiske)

19. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

20. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

19. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 2026-793

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .